本文關(guān)鍵詞：康柏西普和雷株單抗治療濕性年齡相關(guān)性黃斑變性的成本效益比較　出處：《中國(guó)衛(wèi)生標(biāo)準(zhǔn)管理》2016年20期 　論文類型：期刊論文

  更多相關(guān)文章： 雷株單抗 康柏西普 黃斑變性

【摘要】：目的比較康柏西普和雷株單抗治療濕性年齡相關(guān)性黃斑變性的成本和效益。方法回顧性分析我科用雷株單抗(雷株單抗組)和康柏西普(康柏西普組)治療濕性年齡相關(guān)性黃斑變性的臨床效果和費(fèi)用差異。結(jié)果兩組術(shù)前和術(shù)后視力差異均無統(tǒng)計(jì)學(xué)意義(P0.05);雷株單抗組人均醫(yī)療費(fèi)用高于康柏西普組(P0.01)。結(jié)論康柏西普和雷株單抗治療濕性年齡相關(guān)性黃斑變性具有同等的效果,應(yīng)用康柏西普治療的費(fèi)用低于雷株單抗。
[Abstract]:Objective to compare the Xipu Compaq and ray mAb treatment of wet age-related macular degeneration and cost benefit. Methods a retrospective analysis using monoclonal antibody (McAb Lei Lei group) and Compaq SEPR (Compaq SEPR group) the clinical effect and the cost difference between the treatment of wet age-related macular degeneration. Results there were no significant differences the vision of two groups before and after operation (P0.05); Lei mAbs group the average medical expense is higher than that of the Compaq etanercept group (P0.01). Conclusion Xipu Compaq and ray mAb treatment of wet age-related macular degeneration has the same effect, the cost of treatment is lower than the application of Compaq SEPR Lei mAbs.

【作者單位】： 陜西省西安中學(xué);西安市第一醫(yī)院眼科;
【分類號(hào)】：R774.5
【正文快照】： 年齡相關(guān)性黃斑變性(ARMD)是年齡在50歲以上人群中不可逆性中心視功能損害的首位致盲性眼病,其中濕性ARMD對(duì)視功能的損害高于干性ARMD[1]。玻璃體腔注射抗血管內(nèi)皮細(xì)胞生長(zhǎng)因子(VEGF)藥物是治療濕性ARMD的有效方法,目前臨床上應(yīng)用的抗VEGF藥物主要有阿瓦斯丁(Avastin)、雷珠單，

本文編號(hào)：1396921